Monmouth Junction, NJ, October 7th, 2024 – Notitia Biotechnologies, a leader in microbiome-based therapies, announces the publication of a pivotal study in Cell (2024) of by its co-founder, Dr. Liping Zhao, and an international team of collaborators. This landmark research identifies a "Core Microbiome Signature" composed of two key groups of bacteria—the Foundation Guild and Pathobiont Guild—which serve as crucial indicators of gut health.
Utilizing the proprietary Two Competing Guilds (TCG) model, the study reveals a dynamic "seesaw" relationship between these bacterial groups, enabling accurate prediction of individual health status across various demographics. This discovery opens new avenues for personalized medicine, microbiome restoration therapies, and next-generation health diagnostics.
Empowering Health Through Gut Microbiome Analysis
At the heart of this breakthrough discovery is the Foundation Guild, a group of beneficial bacteria responsible for fiber fermentation and producing short-chain fatty acids (SCFAs), essential for metabolic and immune health. The Pathobiont Guild, in contrast, includes bacteria associated with inflammation and disease.
“This study provides scientific validation for our novel microbiome therapy, which aims to restore the balance between these two bacterial guilds to enhance health and prevent disease,” says Jeffrey Zhao, CEO of Notitia Biotechnologies. “Our innovative approach is setting new standards for gut microbiome therapies and disease prevention.”
Targeted Nutrition and Dietary Products: Enhancing the Foundation Guild
Building on this groundbreaking discovery, Notitia is expanding its research into targeted nutrition to promote the growth of the Foundation Guild bacteria. The company’s existing microbiome nutrition product, Guild:Plus, plays a key role in this effort. Guild:Plus is specifically designed to nurture Foundation Guild bacteria through a blend of prebiotics and fibers known to enhance their function, helping to restore gut health in individuals experiencing dysbiosis or imbalance in their microbiota.
Dr. Liping Zhao adds, “Our product development is focused on creating precision nutrition solutions that target the Foundation Guild. Through targeted dietary interventions, such as Guild:Plus, we aim to enrich the beneficial bacteria essential for gut health. These products will give consumers a powerful tool for promoting a healthy microbiome.”
Redefining Health with the Two Competing Guilds Model
Dr. Zhao’s research directly applies to Notitia’s therapeutic pipeline, including the company’s NBT-NM108 and pipelines of other novel microbiome therapies aiming to treat conditions associated with gut dysbiosis. These products are undergoing clinical trials, with plans to demonstrate their potential to address chronic diseases such as type 2 diabetes, inflammatory bowel disease, and more.
“We are advancing the frontier of microbiome science,” Dr. Zhao explains. “By understanding the core microbiome signature, we hope to develop more effective treatments to alleviate a wide range of diseases.”
Nutrition and Health: A Vision for the Future
With the addition of targeted nutrition products like Guild:Plus, Notitia is transforming how the microbiome can be supported through everyday dietary choices. By leveraging insights from the TCG model, Notitia’s products promote the specific growth of health-promoting bacterial guilds while suppressing pathogenic microbes. The ongoing development of these dietary products reflects Notitia’s commitment to improving health outcomes through accessible, nutrition-based solutions.
This breakthrough will be the focus of several upcoming research initiatives and collaborations, with detailed findings and product innovations available on the company’s website.
For more information on how Notitia is transforming microbiome health, please visit www.notitiabio.com and store.notitiabio.com